101
Participants
Start Date
April 9, 2009
Primary Completion Date
May 17, 2017
Study Completion Date
May 17, 2017
Carfilzomib
Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.
Weill Cornell Medical College, New York
Mount Sinai School of Medicine, New York
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
University of Maryland, Greenebaum Cancer Center, Baltimore
Winship Cancer Institute - Emory University, Atlanta
H. Lee Moffitt Cancer Center & Research Institute, Tampa
The Cleveland Clinic Foundation, Cleveland
Gabrail Cancer Center Research, Canton
Northwestern University, Chicago
The University of Texas, MD Anderson Cancer Center, Houston
Northwest Cancer Center, Houston
Texas Oncology Cancer Center, Austin
Colorado Blood Cancer Institute, Denver
Pinnacle Oncology Hematology, Scottsdale
Tower Cancer Research Foundation, Beverly Hills
City of Hope National Medial Center, Duarte
University of California Medical Center, San Francisco
Fred Hutchinson Cancer Research Center, Seattle
Washington University School of Medicine, St Louis
John Theurer Cancer Center at Hackensack UMC, Hackensack
Sarah Cannon Research Institute, Nashville
University of Toronto, Princess Margaret Hospital, Toronto
Jewish General Hospital, Montreal
Lead Sponsor
Amgen
INDUSTRY